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Summary  Eosinophilia  may  be  responsible  for  cardiac  injuries  of  widely  varying  severity,  from
acute myocarditis  to  endomyocardial  ﬁbrosis.  In  this  review,  we  present  both  the  molecular
mechanisms  that  are  responsible  for  these  lesions  and  their  clinical  and  paraclinical  aspects.
Numerous  aetiologies  can  lead  to  severe  eosinophilia,  but  these  are  mainly  represented  by
hypersensitivity  reactions,  rheumatological  diseases  and  hypereosinophilic  syndrome.  Because
cardiac involvement  may  be  extremely  severe,  echocardiography  should  be  always  performed
in the  context  of  eosinophilia  and  appropriate  therapeutics  should  be  started  rapidly  in  order
to limit  the  progression  of  the  disease.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
Abbreviations: CT, computed tomography; DRESS, drug rash with eosinophilia and systemic symptoms; ECG, electrocardiography; ECP,
osinophil cationic protein; ECPA, eosinophilic coronary periarteritis; EDN, eosinophil-derived neurotoxin; EMF, endomyocardial ﬁbrosis; EPO,
osinophil peroxidase; FP, FIP1L1-PDGFRA; GM-CSF, granulocyte macrophage colony-stimulating factor; HES, hypereosinophilic syndrome;
g, immunoglobulin; IL, interleukin; L-HES, lymphocytic hypereosinophilic syndrome; MBP, major basic protein; MRI, magnetic resonance
maging.
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Résumé  Une  hyperéosinophilie  peut  être  responsable  de  lésions  cardiaques  dont  la  sévérité
est très  variable,  allant  de  la  myocardite  aiguë  jusqu’à  la  ﬁbrose  endomyocardique.  Nous
présentons,  à  travers  cette  revue  de  la  littérature,  les  mécanismes  moléculaires  qui  entraî-
nent ces  différentes  lésions  ainsi  que  leurs  aspects  cliniques  et  paracliniques.  Si  de  nombreuses
étiologies  peuvent  être  responsables  d’hyperéosinophilie,  les  réactions  d’hypersensibilité,  les
maladies  rhumatologiques  et  le  syndrome  d’hyperéosinophilie  en  sont  les  principales  causes.
Parce que  l’atteinte  cardiaque  peut  être  extrêmement  sévère,  une  échocardiographie  doit  être
systématiquement  réalisée  en  cas  d’hyperéosinophilie  et  un  traitement  approprié  doit  être
débuté rapidement  aﬁn  de  limiter  la  progression  des  lésions.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Eosinophilic  cardiac  disease  is  a  relatively  rare  condi-
tion  that  was  ﬁrst  described  in  1936  by  Wilhelm  Löfﬂer,
who  called  it  ‘ﬁbroplastic  parietal  endocarditis  with  blood
eosinophilia’  [1].  Also  known  as  Löfﬂer’s  endocarditis,
eosinophilic  endomyocardial  ﬁbrosis  (EMF)  is  an  uncommon
cause  of  restrictive  cardiomyopathy.  In  fact,  several  types
of  cardiac  damage  may  be  encountered  in  the  context  of
eosinophilia,  from  acute  myocarditis  to  EMF.  All  result  from
toxicity  of  inﬁltrating  eosinophils  into  cardiac  tissue.  The
aim  of  this  review  is  to  present  both  the  mechanisms  that
underlie  these  lesions  and  their  clinical  aspects,  imaging
features  and  speciﬁc  treatments.
Physiology and pathophysiology of
eosinophils
Eosinophils  are  normally  found  in  the  blood  and  in  cer-
tain  tissues.  These  granulocytes  are  involved  in  normal
antimicrobial  immunity  [2].  They  have  surface  proteins  for
immunoglobulin  (Ig)E  binding  to  IgE  antigen  complexes  by
which  phagocytosis  and  release  of  granules  is  triggered.
Indeed,  when  stimulated,  eosinophils  possess  the  ability  to
elaborate  substances  that  are  toxic  to  a  wide  variety  of
parasites  that  are  too  large  to  phagocytose  [3].  Their  usual
location  in  the  body  (respiratory  tract,  gastrointestinal  tract
and  skin)  is  therefore  explained  by  this  antiparasitic  activity.
They  measure  12—15  m  in  diameter  and  are  characterized
by  a  bilobed  nucleus  and  numerous  eosin-staining  speciﬁc
granules  in  their  cytoplasm  [4].  These  granules  contain  high
concentrations  of  hydrolases  and  cationic  and  basic  proteins
[5,6]  (Fig.  1  [7]).
Production and kinetics
Along  with  the  other  polymorphonuclear  leukocytes,
eosinophils  are  produced  by  the  bone  marrow,  where  they
represent  up  to  6%  of  the  resident  nucleated  cells  [8].  Under
the  inﬂuence  of  several  cytokines,  the  haematopoietic  stem
cells  gradually  differentiate  into  eosinophilic  myelocytes
and  then  into  mature  eosinophils  (Fig.  1).  This  maturation
b
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erocess  takes  approximately  8  days.  The  main  cytokines
esponsible  for  the  increase  in  eosinophil  number  are  gran-
locyte  macrophage  colony-stimulating  factor  (GM-CSF),
nterleukin  (IL)-3  and  IL-5.  IL-5  —  produced  by  T  helper  2
ymphocytes  —  is  speciﬁc  for  the  production  of  eosinophils
nd  is  considered  to  be  their  major  growth  factor  [9]. It
s  also  involved  in  survival,  chemotaxis  and  degranulation.
osinophils  remain  in  the  peripheral  blood  for  8—12  hours
efore  migrating  preferentially  to  certain  tissues  where  they
re  concentrated:  the  respiratory  tract,  the  gastrointesti-
al  tract,  the  skin  and  the  urogenital  tract  (in  females).
osinophils  survive  for  1—2  weeks  unless  apoptosis  is  pre-
ented  by  cytokines  (GM-CSF,  IL-3,  IL-5)  [8].
omposition
he  cytoplasm  of  eosinophils  is  ﬁlled  with  many  eosin-
taining  speciﬁc  and  non-eosinophilic  granules.  As
osinophils  are  involved  in  the  inﬂammation  process
nd  in  innate  and  adaptive  immunity,  the  speciﬁc  granules
re  capable  of  inducing  tissue  damage  and  dysfunction  by
egranulation  following  activation  by  an  immune  stimulus.
hey  contain  cationic  proteins:  major  basic  protein  (MBP),
osinophil  cationic  protein  (ECP),  eosinophil-derived  neu-
otoxin  (EDN)  and  eosinophil  peroxidase  (EPO)  [9]  (Fig.  1).
hese  proteins  have  several  effects  including  production
f  free  radicals,  cell  necrosis  and  apoptosis  induction.
hese  eosinophilic  constituents  are  very  deleterious  to  the
ndothelial  cells  and  are  capable  of  activating  platelets
nd  impairing  the  anticoagulant  effects  of  thrombomodulin
10]. Finally,  the  endocardium  appears  to  be  very  sensitive
o  the  release  of  these  cardiotoxic  agents,  especially  MBP
nd  ECP  [11].
eﬁnition of eosinophilia
osinophils  are  present  in  the  blood  in  small  numbers:  the
ormal  count  of  circulating  eosinophils  is  ≤  350/mm3,  for
oth  adults  and  children.  Mild  eosinophilia  is  deﬁned  by  a
evel  of  500—1500  eosinophils/mm3.  A  count  of  1500—5000
osinophils/mm3 is  considered  as  moderate  and  >  5000
osinophils/mm3 is  a  signiﬁcant  eosinophilia  [8].
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Figure 1. Eosinophil characteristics and normal kinetics. After production in the bone marrow, eosinophils remain in the peripheral blood
for a few hours before migrating to speciﬁc organs that are involved in antimicrobial immunity. Circulating eosinophils contain numerous red-
orange granules in their cytoplasm. These granules are composed of various cationic proteins, cytokines and lipid mediators. The cationic
proteins — especially major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN) and eosinophil
peroxidase (EPO) — are potent mediators of antimicrobial immunity. These proteins are extremely toxic to heart cells. The production of
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dosinophils is stimulated by cytokines such as granulocyte macroph
eproduced with permission from Séguéla and Acar [7].
ardiac toxicity
he  degree  of  damage  associated  with  eosinophilic  inﬁltra-
ion  of  tissue  appears  to  be  related  to  the  stimulus  attracting
he  eosinophils,  the  duration  of  eosinophilia  and  the  degree
f  eosinophil  activation.  Indeed,  deleterious  effects  on  tis-
ues,  particularly  on  the  heart,  are  more  common  in  cases
f  profound  eosinophilia  (>  5000/mm3).  According  to  Gottdi-
ner  et  al.  [12],  three  phases  are  classically  described.  The
rst  stage  is  due  to  eosinophilic  inﬁltration  into  the  tissues
nd  leads,  after  the  release  of  granular  proteins,  to  cells
ecrosis.  When  biopsies  are  performed,  they  consistently
how  deposits  of  MBP,  ECP  and  EPO.  The  second  phase  is
epresented  by  thrombosis  formation.  Because  the  cationic
roteins  of  eosinophils  bind  to  the  anion-binding  exosite
f  thrombomodulin,  the  complex  thrombomodulin-thrombin
annot  form  and  it  loses  its  anti-thrombotic  role.  Indeed
hrombomodulin,  by  binding  to  the  circulating  thrombin,  is
 potent  physiological  inhibitor  of  coagulation  (Fig.  2  [7]).
he  third  stage  corresponds  to  ﬁbrotic  scarring.  In  the  ﬁnal
tage,  cardiac  endothelium  and  valves  become  ﬁbrotic  and
s
r
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tolony-stimulating factor (GM-CSF), interleukin (IL)-3 and IL-5.
hickened,  resulting  in  a  non-compliant  ventricle,  initially
eﬁned  as  Löfﬂer’s  ﬁbroplastic  endocarditis  [1].
auses of eosinophilia
any  diseases  may  be  responsible  for  eosinophilia  but  not
ll  cause  profound  eosinophilia.  The  most  common  aetiolo-
ies  are  reported  in  Table  1. The  ﬁrst  step  is  to  exclude
eactive  eosinophilia  [13]. Indeed,  some  drugs  (anticonvul-
ants,  non-steroidal  anti-inﬂammatory  drugs,  antimicrobial
gents,  sulfonamides)  are  well  known  to  trigger  an  abnormal
roduction  of  eosinophils.  Eosinophilia  may  be  the  sole  man-
festation  of  a  drug-induced  hypersensitivity  reaction.  When
 drug-related  eosinophilia  is  associated  with  a  morbilliform
ruption  and  severe  tissue  damage,  this  condition  is  called
rug  rash  with  eosinophilia  and  systemic  symptoms  (DRESS)
yndrome  [14].  Withdrawal  of  the  offending  drug  usually
esults  in  normalization  of  the  eosinophil  count  within  7—10
ays  [8].  Cases  of  post-vaccination  eosinophilic  myocardi-
is  (after  smallpox  or  diphtheria/tetanus/pertussis  vaccines)
Eosinophilic  cardiac  injuries  
Figure 2. Actions of thrombomodulin. Thrombomodulin, a cell
surface protein of the endothelium, normally binds to throm-
bin to form the complex thrombomodulin-thrombin. This complex
inhibits platelet activation, activates the conversion of ﬁbrinogen
to ﬁbrin and activates protein C, which is a major physiological
anticoagulant. By binding to the extracellular anionic domain of
thrombomodulin, the cationic proteins of eosinophils prevent the
formation of the complex and cause thrombosis.
Reproduced with permission from Séguéla and Acar [7].
Table  1  Major  causes  of  chronic  eosinophilia
>  1500/mm3.
Reactive  eosinophilia
Drugs  (hypersensitivity)
Anticonvulsants
Non-steroidal  anti-inﬂammatory  drugs
Antimicrobial  agents
Sulfonamides
Infections
Helminths
Human  immunodeﬁciency  virus
Human  T-lymphocyte  virus  I
Tuberculosis
Allergic  diseases
Systemic  diseases
Crohn’s  disease
Churg-Strauss  syndrome
Wegener’s  granulomatosis
Polyarteritis  nodosa
Rheumatoid  arthritis
Cholesterol  crystal  embolism
Malignancies
Hodgkin  lymphoma
Non-Hodgkin  lymphoma
Acute  leukaemia
Systemic  mastocytosis
Hypereosinophilic  syndrome
Lymphocytic  variant
Myeloproliferative  variant
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ave  also  been  reported  [15,16]. Thereby,  in  the  presence
f  signiﬁcant  eosinophilia,  an  empirical  anti-helminthic  drug
herapy  should  be  started  immediately.  Other  aetiologies
re  mainly  represented  by  systemic  diseases,  malignancies
nd  hypereosinophilic  syndrome  (HES).
ypereosinophilic syndrome
ES  is  a  heterogeneous  group  of  rare  haematological
isorders  characterized  by  unexplained  and  sustained
lood  eosinophilia.  Chusid  et  al.  [17]  deﬁned  HES  as  an
osinophilia  >  1500/mm3 for  longer  than  6  months,  with-
ut  any  secondary  cause  and  with  evidence  of  organ
nvolvement.  HES  is  consecutive  to  a  clonal  proliferation  of
yeloid  precursor  cells.  It  occurs  in  several  myeloprolife-
ative  disorders  associated  with  tyrosine  kinase  mutations
r  translocations.  Although  more  common  between  20
nd  50  years  of  age,  this  entity  is  sometimes  encoun-
ered  in  children  and  is  more  common  in  males  [18—20].
hereas  dermatological,  pulmonary  and  gastrointestinal
nvolvement  seems  to  be  more  common,  the  involvement
f  the  cardiovascular  system  represents  the  major  source
f  morbidity  and  mortality  [19]. In  children,  HES  is  com-
only  associated  with  chromosomal  abnormalities.  A  new
lassiﬁcation,  introducing  the  concepts  of  variants,  was
ecently  proposed  [21].  As  their  clinical  presentations,
reatments  and  prognoses  are  different,  two  subtypes  of
ES  must  be  recognized:  a lymphocytic  variant  of  HES  (L-
ES)  and  a  myeloproliferative  variant  or  chronic  eosinophilic
eukaemia.  Bone  marrow  cytogenetic  analysis  and  ﬂuores-
ent  in-situ  hybridisation  are  essential  for  their  diagnosis.
ndeed,  an  FIP1L1-PDGFRA  (FP)  fusion  gene,  created  by  an
00-kb  deletion  at  the  4q12  locus,  was  discovered  in  the
ajority  of  myeloproliferative  variants  [22].  Thus,  patients
ith  FP  mutation  are  likely  to  have  the  myeloproliferative
ariant  of  HES  as  opposed  to  L-HES.  The  product  of  this
usion  gene  is  a  constitutively  active  protein-tyrosine  kinase
apable  of  transforming  haematopoietic  cells  into  eosinophil
recursors.  It  explains  the  fact  that  a  well-known  tyrosine
inase  inhibitor,  imatinib,  is  completely  effective  in  88%  of
P-positive  patients  [22,23].  However,  some  patients  with
yeloproliferative  variant  are  FP-negative  and  therefore  do
ot  respond  to  imatinib.  The  L-HES  variant  is  characterized
y  a  deregulation  of  the  lymphocyte  homeostasis,  resulting
n  an  increased  secretion  of  cytokines  (IL-5).  In  this  case,
orticosteroids  are  the  ﬁrst-line  therapeutic  agents.  For
he  resistant  forms,  an  anti-IL-5  therapy  (mepolizumab)  is
ecommended  [23]. Whereas  the  L-HES  variant  is  less  delete-
ious  for  the  heart,  the  transformation  into  acute  leukaemia
eems  to  be  more  common,  especially  for  children  [18].
osinophilic cardiac injuries
he  heart  is  one  of  the  most  frequently  involved  organs
n  cases  of  sustained  eosinophilia  [17,18].  In  the  Löfﬂer’s
ost-mortem  examination  of  two  patients  with  chronic
osinophilia,  cardiac  involvement  was  characterized  by
brosis  that  obliterated  the  ventricles  [1].  It  is  now  recog-
ised  that  EMF  is  the  ultimate  form  of  eosinophilic  cardiac
isease.  Classically,  cardiac  injuries  of  eosinophilia  are
2 P.-E.  Séguéla  et  al.
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Figure 3. Echocardiographic and cardiac magnetic resonance
imaging (MRI) features of eosinophilic myocarditis in a 5-year-old
child with reactive eosinophilia (hypersensitivity reaction to antibi-
otics): (A) transthoracic echocardiographic apical four-chamber
view showing the thickened free wall of the left ventricle (LV) (yel-
low star) due to interstitial myocardial oedema resulting from a
profound inﬁltration of eosinophils; (B) MRI delayed-enhancement
image in the four-chamber view showing diffuse subendocardial
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ivided  into  three  chronological  phases:  eosinophilic  inﬁl-
ration,  thrombosis  and  ﬁbrosis  [12].
ndomyocardial injuries: three successive
hases
osinophilic myocarditis (acute necrotic stage)
he  early  phase  is  characterized  by  an  eosinophilic  endomy-
carditis  with  eosinophil  and  lymphocyte  inﬁltration  [23].
hen  inﬁltrating  cardiac  tissues,  eosinophils  degranulate
nd  release  toxic  cationic  proteins,  thus  inducing  necrosis
nd  apoptosis.  However,  patients  generally  have  no  car-
iac  symptoms  during  this  stage  and  they  may  present
nly  non-speciﬁc  signs  [24].  Clinical  and  in  vivo  recogni-
ion  of  eosinophilic  myocarditis  is  infrequent,  whereas  it
ccounts  for  up  to  0.5%  of  unselected  myocarditis  autopsy
eries  [25].  Electrocardiography  (ECG)  may  show  sinus
achycardia,  supraventricular  tachycardia,  non-speciﬁc  ST-
egment  anomalies  or  conduction  delays,  but  is  often
nremarkable.  Echocardiography  reveals  an  increased  left
entricular  wall  thickness  because  of  interstitial  myocar-
ial  oedema  (Fig.  3A,  Video  1).  Endomyocardial  biopsy
s  necessary  to  make  the  diagnosis  and  to  differentiate
osinophilic  myocarditis  from  other  types  of  myocarditis.
ndeed,  histological  sections  show  eosinophilic  inﬁltration  of
he  endocardium  and  subendocardial  interstitium,  evidence
f  myocardial  necrosis  and  sometimes  eosinophilic  granulo-
as  (Fig.  4)  [25,26].  At  this  stage  of  the  disease,  the  aim  of
reatment  is  to  rapidly  lower  the  eosinophil  count  in  order
o  limit  myocardial  necrosis.
Acute  narcotising  eosinophilic  myocarditis  represents  the
ost  severe  form  of  acute  eosinophilic  heart  disease  and
ay  be  rapidly  fatal  without  early  diagnosis  and  appro-
riate  treatment  [24,27].  Patients  present  acute  heart
ailure  symptoms  or  may  have  cardiogenic  shock  imme-
iately.  ECG  shows  conduction  abnormalities  and  diffuse
T-segment  elevation.  The  level  of  troponin  is  elevated,
imicking  acute  myocardial  infarction  [28,29].  Echocardi-
graphy  shows  a  left  ventricular  systolic  dysfunction  with
all  motion  abnormalities.  In  this  context,  cardiac  mag-
etic  resonance  imaging  (MRI)  seems  to  be  very  efﬁcient
or  depicting  the  endomyocardial  involvement  [30]. Indeed,
he  endocardial  inﬂammation  is  well  detected  by  the
se  of  delayed-enhancement  sequences  (Fig.  3B)  showing
xtensive  eosinophilic  inﬁltrates  and,  sometimes,  a  patchy
istribution  of  gadolinium  enhancement.  Moreover,  cine
equences  can  accurately  assess  ventricular  function.
Eosinophilic  myocarditis  resulting  from  a  hypersensitiv-
ty  mechanism  may  present  with  normal  or  mildly  elevated
eripheral  eosinophil  counts.  In  all,  50%  of  patients  have
o  eosinophilia  at  the  onset  of  disease.  It  results  from  the
igration  of  circulating  eosinophils  into  the  tissue,  while
one  marrow  cannot  respond  immediately  with  increased
roduction  [31].  Thus,  repeated  white  blood  count  exami-
ations  are  important  in  case  of  myocarditis  with  initially
bsent  eosinophilia.  Symptoms  of  congestive  heart  failure
ave  to  be  treated  with  conventional  drugs.  Because  corti-
osteroid  therapy  inhibits  the  degranulation  of  eosinophils,
t  has  been  proposed  as  a  ﬁrst-line  treatment  for  eosinophilic
yocarditis  in  order  to  limit  myocardial  necrosis.  However,
he  efﬁcacy  of  corticosteroids  remains  controversial  [32,33].
A
t
o
cnhancement (arrows) of the free wall of the LV. LA: left atrium;
V: right ventricle.
n  case  of  fulminant  heart  failure,  mechanical  support  may
e  necessary.
hrombotic stage
s  the  eosinophilic  activation  continues,  patients  may
resent  the  second  stage  of  the  disease,  with  formation
f  mural  thrombi  along  the  damaged  endocardium.  Several
echanisms  have  been  proposed  to  explain  this  thrombosis.
s  previously  mentioned,  eosinophilic  proteins  can  bind  to
hrombomodulin,  thus  impairing  the  anticoagulant  property
f  the  endothelial  membrane  [34].  Furthermore,  factors  of
oagulation  may  be  activated  by  the  granular  proteins  of
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Figure 4. Endomyocardial biopsy of eosinophilic myocarditis: (A) extensive eosinophilic inﬁltrate involving the endocardium and the
myocardium (haematoxylin and eosin); (B) subendocardial granulomas consisting of central amorphous granular material (arrowheads)
surrounded by histiocyte-like elements and a marked eosinophilic inﬁltra
Reproduced with permission from Corradi et al. [26].
eosinophils  [23].  Thrombi  most  commonly  involve  both  ven-
tricles  at  the  apex  and  may  extend  to  the  ventricular  outﬂow
tracts,  the  subvalvular  regions  and  occasionally  the  atrium.
Mural  thrombi  are  well  recognized  both  by  echocardiography
(Fig.  5,  Video  2)  and  cardiac  MRI.  Nevertheless,  cardiac  MRI
seems  to  be  more  sensitive  and  speciﬁc  for  the  detection  of
ventricular  thrombi  than  echocardiography  [35].
Thromboembolic  events  have  been  reported  to  occur
in  4—29%  of  adult  patients  with  idiopathic  eosinophilia
[17,36,37].  Thus,  in  cases  of  organized  thrombi,  oral  anti-
coagulation  therapy  appears  to  be  legitimate  [38,39]. To
prevent  embolic  events,  the  best  target  international  nor-
malized  ratio  value  seems  to  be  3.0.  Antiplatelet  therapy  has
also  been  proposed  to  prevent  the  formation  of  thrombi  at
the  stage  of  eosinophilic  myocarditis.  However,  no  study  has
Figure 5. Transthoracic echocardiography of a 50-year-old
woman with Wegener’s disease. Apical four-chamber view showing
an apical mural thrombus (arrows) of the two ventricles. End-
diastolic volumes are small because of the apical masses. LA: left
atrium; LV: left ventricle; RA: right atrium; RV: right ventricle.
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fte with signs of myocyte necrosis (haematoxylin and eosin).
een  conducted  to  evaluate  the  effectiveness  and  modali-
ies  of  these  treatments.
ibrotic (scarring) stage
inally,  the  formation  of  thrombi  is  followed  by  the  ﬁbrotic
tage,  which  corresponds  to  scarring  of  the  endomy-
cardium.  Fibrosis,  an  irreversible  damage,  involves  the  two
entricles  (Fig.  6  [40]) and  may  include  subvalvular  appa-
atus  of  both  mitral  and  tricuspid  valves  [41,42].  In  their
chocardiographic  series,  Gottdiener  et  al.  [12]  found  mitral
egurgitation  in  43%  of  patients  with  HES.  Indeed,  the  accu-
ulation  of  thromboﬁbrotic  material  between  the  mural
ndocardium  of  the  left  ventricular  free  wall  and  the  ven-
ricular  aspect  of  the  posterior  mitral  leaﬂet  limited  the
osterior  mitral  leaﬂet  motion  (Fig.  7) [43]. In  addition  to
hese  valvular  attachments,  EMF  is  responsible  for  restric-
ive  cardiomyopathy  of  very  poor  prognosis.  EMF  may  also
lter  the  cardiac  conduction  system  leading  to  severe  ven-
ricular  arrhythmias  [44].
At  this  stage,  echocardiography  allows  visualization  of
trioventricular  valve  regurgitation;  and  spectral  Doppler
ow  patterns  across  the  mitral  valve  and  pulmonary  veins
re  consistent  with  restrictive  ﬁlling.  Echocardiographic
riteria  have  been  proposed  to  assess  the  severity  of  EMF
Table  2  [35]).  Endomyocardial  biopsy  shows  marked  EMF,
lassically  in  the  absence  of  any  residual  eosinophilic  inﬁl-
rate  [40]  (Fig.  6).  EMF  is  well  depicted  by  cardiac  MRI,  and
ine  sequences  are  useful  to  demonstrate  diastolic  dysfunc-
ion  [45—48]  (Fig.  8).  On  cardiac  catheterization,  the  typical
aemodynamic  feature  is  the  dip-and-plateau,  or  square
oot,  sign  [49,50].  This  restrictive  ﬁlling  pattern  can  also
e  well  analysed  by  strain  echocardiography  [51].
Surgery  is  often  the  only  efﬁcient  treatment  at  this
tage  of  the  disease.  Endocardial  decortication  provides
cceptable  results  by  prolonging  survival  [52—54].  Indeed,
fter  endomyocardectomy,  70%  of  patients  have  revealed
mprovements  of  symptoms  [55].  When  valvular  regurgi-
ation  is  important,  valvular  surgery  may  be  considered,
nd  bioprosthetic  valve  replacement  is  commonly  pre-
erred  to  mechanical  prosthesis  [56,57].  Indeed,  recurrent
264  P.-E.  Séguéla  et  al.
Table  2  Criteria  for  the  diagnosis  and  assessment  of  severity  of  endomyocardial  ﬁbrosis.
Scorea
Major  criteria
Endomyocardial  plaques  >  2  mm  thickness  2
Thin  (≤  1  mm)  endomyocardial  patches  affecting  >  1  ventricular  wall  3
Obliteration  of  the  right  or  left  ventricular  apex  4
Thrombi  or  spontaneous  contrast  without  severe  ventricular  dysfunction  4
Retraction  of  the  right  ventricular  apex 4
Atrioventricular  valve  dysfunction  due  to  adhesion  of  the  valvular  apparatus  to  the  ventricular  wall 1—4b
Minor  criteria
Thin  endomyocardial  patches  localized  to  one  ventricular  wall 1
Restrictive  ﬂow  pattern  across  mitral  or  tricuspid  valves 2
Pulmonary  valve  diastolic  opening  2
Diffuse  thickening  of  the  anterior  mitral  leaﬂet  1
Enlarged  atrium  with  normal-sized  ventricle  2
M-movement  of  the  septum  and  ﬂat  posterior  wallc 1
Enhanced  density  of  the  moderator  or  other  bands 1
Reproduced with permission from Kleinfeldt et al. [35].
a A deﬁnite diagnosis of endomyocardial ﬁbrosis can be made in the presence of two major criteria or one major criterion associated
with two minor criteria. A total score < 8 indicates mild endomyocardial ﬁbrosis, 8—15 moderate disease and > 15 severe disease.
b The score is assigned according to the severity of atrioventricular regurgitation.
c M-movement of the interventricular septum refers to a pattern of movement observed on M-mode echocardiography that is thought
to be due to obliteration or restriction of the left ventricular apex combined with mitral regurgitation.
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dhrombotic  events  are  more  common  with  the  use  of
echanical  valves  [58].  Ultimately,  orthotopic  heart  trans-
lantation  should  be  considered,  providing  good  results  [40].
n  any  case,  it  is  necessary  to  control  eosinophilia  by  medical
reatments  before  considering  any  surgical  therapy.
ericardial injury
ndomyocardial  involvement  is  often  associated  with
ericardial  effusion,  thus  characterizing  myopericarditis.
owever,  isolated  acute  eosinophilic  pericarditis  has  also
een  reported  [59,60],  as  well  as  eosinophilic  cardiac  tam-
onade  [61].  Finally,  pericardial  involvement  of  eosinophilia
ay  occur  as  constrictive  pericarditis  [62].
oronary lesions
osinophilic  coronary  periarteritis  (ECPA),  also  described
s  ‘isolated  eosinophilic  coronary  arteritis’,  ‘eosinophilic
rteritis’,  ‘eosinophilic  coronary  arteritis’,  ‘limited  form
f  Churg-Strauss  syndrome’,  ‘hypersensitivity-associated
cute  coronary  syndromes’  and  ‘Kounis  syndrome’,  is  a  rare
biquitous  disease  affecting  patients  of  any  age,  and  clas-
ically  diagnosed  at  post-mortem  examination  [63].  Almost
ll  patients  with  ECPA  have  anginal  pain  for  several  weeks  or
ears  before  sudden  death  [64].  Vasospastic  angina  mainly
ppears  from  the  evening  to  the  early  morning  (Prinzmetal’s
asospastic  angina),  and  patients  usually  die  in  the  early
orning.  Despite  the  fact  that  bronchial  asthma  or  drug
llergy  is  generally  not  found,  ECPA  is  believed  to  be  a
istinct  coronary  disease  due  to  a  localized  inﬂammatory
eaction  rather  than  a  limited  form  of  a  primary  vasculi-
is  [64,65].  At  autopsy,  epicardial  coronary  arteries  (from
he  main  stem  to  their  large  branches)  are  grayish-white  in
a
a
a
molour  and  elastically  hard.  ECPA  is  reported  to  frequently
e  accompanied  by  spontaneous  coronary  arterial  dissection
n  the  affected  wall,  especially  in  women  [64].  Histologi-
al  examination  shows  a  severe  inﬂammatory  inﬁltration,
ainly  eosinophils,  of  the  adventitia  and  periadventitial
oft  tissue.  The  intima  and  media  are  usually  intact.  In
omparison,  coronary  lesions  of  Churg-Strauss  syndrome
re  characterized  by  the  presence  of  ﬁbrinoid  necrosis
nd/or  granulomatous  inﬂammation.  Only  a  few  cases  of
he  isolated  cardiac  form  of  polyarteritis  nodosa  have  been
escribed  so  far,  and  for  all  of  them,  coronary  arteritis  was
istributed,  not  only  in  epicardial  large  coronary  arteries
ut  also  in  intramyocardial  small  arteries.  Furthermore,  in
olyarteritis  nodosa,  the  inﬁltration  of  inﬂammation  cells
as  throughout  the  vascular  wall  with  ﬁbrinoid  necrosis
66,67].  Thus,  ECPA  must  be  differentiated  from  medium-
ized  arteritis  with  eosinophilic  inﬁltration  due  to  primary
asculitis.  Because  diagnosis  of  ECPA  is  very  difﬁcult  to  make
t  the  clinical  examination  stage,  vasospastic  angina  associ-
ted  with  eosinophilia  and/or  asthma  and/or  allergy  should
uggest  ECPA,  leading  to  corticoids  therapy.
ropical endomyocardial ﬁbrosis
ropical  EMF  is  the  most  common  cause  of  restrictive  car-
iomyopathy  worldwide  [68].  As  Davies  was  the  ﬁrst  to
escribe  the  clinico-pathological  features  of  tropical  EMF  in
948  [69], this  cardiomyopathy  is  sometimes  called  Davies
isease.  Tropical  EMF  is  endemic  in  tropical  and  sub-tropical
reas,  especially  in  Africa.  Because  the  cardiac  lesions
re  similar  to  those  observed  in  eosinophilic  EMF,  some
uthors  have  suggested  that  the  two  diseases  have  a  com-
on  pathogenesis  involving  eosinophilic  toxicity  [70—72].
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Figure 6. Gross anatomy and endomyocardial biopsy of endomy-
ocardial ﬁbrosis in a 48-year-old male with myeloproliferative
neoplasm (FIP1L1-PDGFRA rearrangement): (A) cross section of an
expanded heart with marked left ventricular hypertrophy and endo-
cardial ﬁbrosis with multiple superﬁcial haemorrhages. The patient
had a hypereosinophilic syndrome and was positive for the FIP1L1-
PDGFR gene rearrangement; (B) gross endocardial ﬁbrosis (EF) with
no cellular inﬁltrates. M: myocardium.
Reproduced with permission from Korczyk et al. [40].
Figure 8. Features of endomyocardial ﬁbrosis in a 20-year-old
man with Epstein-Barr virus-associated lymphoma: (A) four-
chamber computed tomography (CT) scan image showing thickened
walls of the two ventricles; (B) magnetic resonance imaging (MRI)
high-resolution delayed-enhancement four-chamber view showing
a ‘three-layered’ appearance of the ventricular walls: the middle
layer (thin white arrows) shows hyperenhancement secondary to
ﬁbrosis; the innermost layer consists of non-enhancing endocardial
thrombus (thick yellow arrows) and mainly affects apices; pericar-
dial and bilateral pleural effusions are also well depicted (blue
stars). LV: left ventricle; RV: right ventricle.
Figure 7. Transthoracic echocardiography of mitral regurgitation resulting from endomyocardial ﬁbrosis: apical four-chamber view demon-
strating the mechanism of mitral regurgitation in (A) diastole and (B) systole; the posterior mitral leaﬂet (arrow in A) has a restrictive motion
because of abnormal attachments to the left ventricular wall; (C) colour Doppler mode showing the severity of mitral regurgitation; a severe
tricuspid regurgitation reﬂects high ﬁlling pressures (restrictive cardiomyopathy). LA: left atrium; LV: left ventricle; RA: right atrium; RV:
right ventricle.
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[66  
ndeed,  the  high  prevalence  of  parasitic  infections  in  the
ropics  was  assumed  to  be  the  cause  of  a  transient  or  sus-
ained  eosinophilia,  leading  to  the  cardiac  lesions.  This
ypothesis  was  supported  by  observations  of  visitors  to  sub-
ropical  regions  who  developed  tropical  EMF  [73].  However,
he  variable  association  with  eosinophilia  and  the  frequent
bsence  of  eosinophils  on  endomyocardial  biopsies,  even
n  the  early  stages,  are  arguments  against  this  assumption
68—74].  Thus,  exact  mechanisms  of  tropical  EMF  remain
nknown.  A  new  hypothesis  involves  an  infective  trigger  in
enetically  susceptible  individuals  [74].
onclusions
echanisms  that  explain  why,  in  sustained  eosinophilia,  the
eart  is  particularly  targeted  by  eosinophils  are  not  well
nderstood.  Nonetheless,  a  profound  eosinophilic  inﬁltra-
ion  of  the  interstitial  compartment  is  very  deleterious
o  cardiac  tissues.  Clinical  and  echocardiographic  signs
f  eosinophilic  cardiac  disease  may  vary  widely.  As  early
reatment  can  limit  irreversible  damage,  echocardiography
hould  be  systematically  performed  in  cases  of  eosinophilia,
specially  if  it  is  prolonged.  In  the  absence  of  aetiology,
rst-line  treatment  should  include  anti-helminthic  therapy,
orticosteroid  therapy  and  anticoagulant  therapy.  The  goal
f  these  therapeutics  is  to  rapidly  lower  the  eosinophil  count
nd  prevent  thromboembolic  events.  As  second-line  treat-
ent,  speciﬁc  treatment  of  eosinophilia  must  be  conducted
epending  on  the  cause.  Finally,  surgery  may  be  neces-
ary  at  the  ﬁbrotic  stage  of  the  disease,  before  considering
eart  transplantation  for  the  most  severe  cases.  Eosinophilic
oronary  periarteritis  is  a  rare  isolated  eosinophilic  injury
ocalized  to  epicardial  coronary  arteries,  which  is  responsi-
le  for  vasospastic  angina.  For  all  of  these  lesions,  prognosis
s  related  to  the  severity  of  cardiac  injuries  but  also  to  the
ause  of  eosinophilia.
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